Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691427 · ClinicalTrials.gov registry record · Early Phase 1
Effectiveness of Virtual Reality Vision Therapy - VERVE
A Early Phase 1 study of Convergence Insufficiency, sponsored by OculoMotor Technologies.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT04691427: Recruiting Early Phase 1 study of Convergence Insufficiency, sponsored by OculoMotor Technologies.
NCT04691427 is a Early Phase 1 study of Convergence Insufficiency that is actively recruiting participants, run by OculoMotor Technologies. The registered enrollment target is 50 participants, below the 117-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04691427, a Early Phase 1 study of Convergence Insufficiency, is actively recruiting participants, sponsored by OculoMotor Technologies.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.
Conditions Studied
Interventions
- DEVICE Virtual Eye Rotation Vision Exercises (VERVE)
Study Locations (2)
New Jersey
- OculoMotor Technologies - Newark
Pennsylvania
- The Eye Institute at Salus University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2024-09 |
| Phase | Early Phase 1 |
What NCT04691427 shows while recruiting
NCT04691427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 117-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Convergence Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which Virtual Eye Rotation Vision Exercises (VERVE) is the first listed.
NCT04691427 reports a single indexed study location in New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04691427 about?
NCT04691427 is a clinical study titled "Effectiveness of Virtual Reality Vision Therapy - VERVE". The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find ...
What is the current status of trial NCT04691427?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2021-10-14. Estimated completion is 2024-09.
What conditions does trial NCT04691427 study?
This clinical trial studies the following conditions: Convergence Insufficiency.
What interventions are being tested in trial NCT04691427?
The interventions under investigation include: Virtual Eye Rotation Vision Exercises (VERVE) (DEVICE).
Who is sponsoring clinical trial NCT04691427?
This trial is sponsored by OculoMotor Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04691427 being conducted?
This trial has 2 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Convergence Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home-based Vision Therapy
RECRUITING · Phase 1
-
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
RECRUITING · NA
-
Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency
RECRUITING · NA
-
Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency
COMPLETED · NA
-
A Prospective Observational Study of Adult Strabismus
COMPLETED
-
Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI